Dashboard

BeyondSpring, Inc. (BYSI)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

CEO

Lan Huang

Employees

52

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

New York

Exchange

NASDAQ

Summary Stats

Market Cap

41.7M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 2 analysts

High

$43.00

Average

$39.00

Low

$35.00

Ratings calculated by 3 analysts

Buy

3

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q4 2021

Last Earnings

Above by $0.02

Actual

-$0.24 +7.7%

Consensus

-0.26

Report Date

Year Ago

-0.52

Year Ago Change %

Up 53%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites